CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...